Anpario PLC (LON:ANP) Stock Rating Reconfirmed by Analysts at Peel Hunt; The GBX 425.00 Target Indicates -13.27% Potential; 683 Capital Management Has Raised Galmed Pharmaceuticals LTD (GLMD) Stake

683 Capital Management Llc increased Galmed Pharmaceuticals Ltd (GLMD) stake by 9.86% reported in 2017Q3 SEC filing. 683 Capital Management Llc acquired 49,295 shares as Galmed Pharmaceuticals Ltd (GLMD)’s stock rose 17.66%. The 683 Capital Management Llc holds 549,295 shares with $5.02 million value, up from 500,000 last quarter. Galmed Pharmaceuticals Ltd now has $139.30M valuation. The stock decreased 0.55% or $0.06 during the last trading session, reaching $10.94. About 37,525 shares traded. Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) has risen 0.41% since January 29, 2017 and is uptrending. It has underperformed by 16.29% the S&P500.

Peel Hunt have a GBX 425.00 PT on the stock. The PT would suggest a potential downside of -13.27% from Anpario PLC (LON:ANP)‘s last stock price. This rating was revealed to clients and investors in a research report on Monday morning.

The stock decreased 6.09% or GBX 30 during the last trading session, reaching GBX 463. About 35,497 shares traded or 130.60% up from the average. Anpario plc (LON:ANP) has 0.00% since January 29, 2017 and is . It has underperformed by 16.70% the S&P500.

Anpario plc, together with its subsidiaries, produces and distributes natural feed additives for animal health, hygiene, and nutrition worldwide. The company has market cap of 107.04 million GBP. The company's product categories include eubiotics, feed security, feed quality, and nutritional. It has a 33.55 P/E ratio. The Company’s eubiotic category includes a range of products that support and maintain animal gut health; feed quality category contains products, such as enzymes, anti-oxidants, and pellet binders; feed security products comprise mycotoxin binders, insect control, water sanitation, and hygiene; and nutritional category contains omega fatty acids range of products.

Among 2 analysts covering Anpario PLC (LON:ANP), 0 have Buy rating, 0 Sell and 2 Hold. Therefore 0 are positive. Anpario PLC has GBX 432 highest and GBX 330 lowest target. GBX 428.50’s average target is -7.45% below currents GBX 463 stock price. Anpario PLC had 12 analyst reports since March 8, 2016 according to SRatingsIntel. The stock has “Buy” rating by Peel Hunt on Tuesday, June 28. Peel Hunt maintained the stock with “Buy” rating in Wednesday, March 8 report. Peel Hunt maintained the shares of ANP in report on Thursday, June 29 with “Buy” rating. The stock has “Buy” rating by Peel Hunt on Wednesday, September 14. The stock has “Buy” rating by N+1 Singer on Thursday, June 29. The stock has “Hold” rating by Peel Hunt on Monday, January 29. Peel Hunt maintained Anpario plc (LON:ANP) on Tuesday, March 8 with “Buy” rating. Peel Hunt downgraded it to “Hold” rating and GBX 425 target in Monday, November 13 report. The firm earned “Buy” rating on Tuesday, September 19 by Peel Hunt. As per Tuesday, September 19, the company rating was maintained by N+1 Singer.

683 Capital Management Llc decreased Peabody Energy Corp New stake by 116,960 shares to 269,400 valued at $7.82 million in 2017Q3. It also reduced Jpmorgan Chase & Co (AMJ) stake by 30,000 shares and now owns 220,000 shares. Warrior Met Coal Inc was reduced too.

Among 5 analysts covering Galmed Pharmaceuticals Ltd (NASDAQ:GLMD), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Galmed Pharmaceuticals Ltd has $32 highest and $1400 lowest target. $20.40’s average target is 86.47% above currents $10.94 stock price. Galmed Pharmaceuticals Ltd had 7 analyst reports since August 14, 2015 according to SRatingsIntel. H.C. Wainwright reinitiated the stock with “Buy” rating in Monday, March 28 report. As per Tuesday, August 8, the company rating was maintained by H.C. Wainwright. The stock of Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) earned “Buy” rating by Maxim Group on Monday, July 31. Roth Capital maintained the stock with “Buy” rating in Thursday, August 13 report.

Free Email Newsletter

Enter your email address below to get the latest news and analysts’ ratings for your stocks with our free daily email newsletter: